Published in Thromb Haemost on October 01, 1998
Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost (2009) 4.95
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost (2004) 2.21
Effect on blood lipids, coagulation, and fibrinolysis of a fat high in myristic acid and a fat high in palmitic acid. Am J Clin Nutr (1994) 2.12
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost (2012) 2.04
Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation (1996) 1.80
Ambulatory 24-hr pH monitoring of esophagus, fundus, and antrum. A new technique for simultaneous study of gastroesophageal and duodenogastric reflux. Dig Dis Sci (1990) 1.76
An extensive analysis of Y-chromosomal microsatellite haplotypes in globally dispersed human populations. Am J Hum Genet (2001) 1.70
Standardisation of oral anticoagulant treatment. Br Med J (Clin Res Ed) (1984) 1.60
A collaborative calibration study of reference materials for thromboplastins. Thromb Haemost (1983) 1.53
Effect of daptomycin on prothrombin time and the requirement for outlier exclusion in International Sensitivity Index calibration of thromboplastin. J Thromb Haemost (2007) 1.49
Four cases of aggressive MRSA wound infection following head and neck surgery. J Laryngol Otol (1997) 1.48
Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet (1998) 1.47
Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med (1996) 1.46
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal. J Thromb Haemost (2011) 1.45
Field test of arousal: a portable reaction timer with data storage. Hum Factors (1982) 1.45
A comparison of artificially-depleted, lyophilized coumarin and fresh coumarin plasmas in thromboplastin calibration. European Concerted Action on Anticoagulation. Br J Haematol (1998) 1.44
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
Effect of evacuated blood collection tubes on thromboplastin calibration. Thromb Haemost (1998) 1.43
Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group. Thromb Haemost (1991) 1.40
A simplified statistical method for local INR using linear regression. European Concerted Action on Anticoagulation. Br J Haematol (1997) 1.40
The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over-anticoagulation. J Thromb Haemost (2012) 1.40
Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. J Am Coll Cardiol (1991) 1.39
Is there a need for replacement of the International Reference Preparation for Thromboplastin, Bovine, Combined (OBT/79)? J Thromb Haemost (2005) 1.39
Calibration of local systems with lyophilized calibrant plasmas improves the interlaboratory variability of the INR in the Italian external quality assessment scheme. Thromb Haemost (1999) 1.38
Effects of inhalable particulate matter on blood coagulation. J Thromb Haemost (2009) 1.34
The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest (1985) 1.22
Is it only a mechanical matter? Histologic modifications of the aorta underlying external banding. J Thorac Cardiovasc Surg (1999) 1.21
Experiences with vaccination in countries endemically infected with highly pathogenic avian influenza: the Food and Agriculture Organization perspective. Rev Sci Tech (2009) 1.20
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost (2009) 1.19
The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost (1989) 1.19
Are olive oil diets antithrombotic? Diets enriched with olive, rapeseed, or sunflower oil affect postprandial factor VII differently. Am J Clin Nutr (1999) 1.18
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost (2013) 1.16
Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb Haemost (1985) 1.15
Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb (1993) 1.14
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal. J Thromb Haemost (2013) 1.12
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal. J Thromb Haemost (2013) 1.10
Considerations on the true value of the international normalized ratio in the control of oral anticoagulant therapy. Br J Haematol (1994) 1.07
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost (2011) 1.06
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost (2011) 1.05
Laboratory screening of inherited thrombotic syndromes. Thromb Haemost (1987) 1.05
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol (1999) 1.05
Effect of sodium intake on gentamicin nephrotoxicity in the rat. Proc Soc Exp Biol Med (1976) 1.04
Genetic influence on thrombotic risk markers in the elderly--a Danish twin study. J Thromb Haemost (2005) 1.02
Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost (2012) 1.01
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost (2008) 1.00
Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions. Thromb Haemost (1987) 0.99
Localized dissection and delayed rupture of the abdominal aorta after extracorporeal shock wave lithotripsy. J Vasc Surg (2000) 0.98
Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding. Thromb Haemost (1986) 0.98
A proposed scheme for calibration of international reference preparations of thromboplastin for the prothrombin time. On behalf of the Subcommittee on Control of Anticoagulation. Thromb Haemost (1995) 0.96
European Concerted Action on Anticoagulation (ECAA)-the multicentre calibration of rabbit and human ECAA reference thromboplastins. Steering Committee. Thromb Haemost (1996) 0.96
Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res (1996) 0.96
Inherited factors in thrombosis. Blood Rev (1988) 0.95
Minimum lyophilized plasma requirement for ISI calibration. European Concerted Action on Anticoagulation. Am J Clin Pathol (1998) 0.95
Outside-inside distribution and translocation of lysophosphatidylcholine in phosphatidylcholine vesicles as determinied by 13C-NMR using (N-13CH3)-enriched lipids. Biochim Biophys Acta (1977) 0.95
The International Normalized Ratio (INR) in the MELD score: problems and solutions. Am J Transplant (2010) 0.95
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. J Thromb Haemost (2011) 0.94
Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost (2000) 0.94
The first specific detection of a highly pathogenic avian influenza virus (H5N1) in Ivory Coast. Zoonoses Public Health (2008) 0.94
Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int (2000) 0.93
European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of point-of-care prothrombin time monitor systems. Br J Haematol (2002) 0.93
Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids. Atherosclerosis (1990) 0.92
The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy--a prospective, randomized, double-blind, placebo-controlled study. Scand J Urol Nephrol (2000) 0.92
European Concerted Action on Anticoagulation (ECAA). An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors. J Clin Pathol (2003) 0.92
The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. Atherosclerosis (1992) 0.92
Fat high in stearic acid favorably affects blood lipids and factor VII coagulant activity in comparison with fats high in palmitic acid or high in myristic and lauric acids. Am J Clin Nutr (1994) 0.92
Herpes simplex virus nuclear nonvirion antigens detected by anticomplement immunofluorescence. Tumori (1977) 0.92
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med (1998) 0.91
Longevity is independent of common variations in genes associated with cardiovascular risk. Thromb Haemost (1999) 0.91
Kinetic model of the protein-mediated phosphatidylcholine exchange between single bilayer liposomes. Biochemistry (1975) 0.91
Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis. Am J Med (1977) 0.91
Protein S deficiency associated with "juvenile" arterial and venous thromboses. Thromb Haemost (1986) 0.91
HLA-DRB1*0102 is associated with TINU syndrome and bilateral, sudden-onset anterior uveitis but not with interstitial nephritis alone. Br J Ophthalmol (2010) 0.90
The effect of sample size on fresh plasma thromboplastin ISI determination. Br J Haematol (1999) 0.90
European Concerted Action on Anticoagulation--comparison of fresh plasma and whole blood multicentre ISI calibrations of CoaguChek Mini and TAS PT-NC whole blood prothrombin time point-of-care monitors. Thromb Haemost (2002) 0.90
Quality control of prothrombin time determinations in the Netherlands. Scand J Haematol Suppl (1980) 0.89
Inflammation, thrombosis and atherosclerosis: results of the Glostrup study. J Thromb Haemost (2003) 0.89
Transbilayer distribution and movement of lysophosphatidylcholine in liposomal membranes. Biochim Biophys Acta (1977) 0.88
Effect of fish diet versus meat diet on blood lipids, coagulation and fibrinolysis in healthy young men. J Intern Med (1991) 0.88
Post-operative blood loss after transurethral prostatectomy is dependent on in situ fibrinolysis. Br J Urol (1997) 0.88